US20010008884A1 - Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter - Google Patents
Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter Download PDFInfo
- Publication number
- US20010008884A1 US20010008884A1 US09/214,314 US21431499A US2001008884A1 US 20010008884 A1 US20010008884 A1 US 20010008884A1 US 21431499 A US21431499 A US 21431499A US 2001008884 A1 US2001008884 A1 US 2001008884A1
- Authority
- US
- United States
- Prior art keywords
- neuropathy
- vitamin
- neurotransmitter
- treatment
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 39
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 239000000935 antidepressant agent Substances 0.000 title claims abstract description 19
- 229940005513 antidepressants Drugs 0.000 title claims abstract description 19
- 239000002858 neurotransmitter agent Substances 0.000 title claims abstract description 19
- 239000002243 precursor Substances 0.000 title claims abstract description 18
- 239000000411 inducer Substances 0.000 title claims abstract description 17
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 title claims abstract description 6
- 239000002899 monoamine oxidase inhibitor Substances 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title abstract description 4
- 208000027232 peripheral nervous system disease Diseases 0.000 title description 6
- RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 title 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 28
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract 4
- 239000011718 vitamin C Substances 0.000 claims abstract 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 27
- 201000001119 neuropathy Diseases 0.000 claims description 19
- 230000007823 neuropathy Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- 229960002813 lofepramine Drugs 0.000 claims description 11
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 11
- 208000005877 painful neuropathy Diseases 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 10
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 claims description 6
- 229960004799 tryptophan Drugs 0.000 claims description 6
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229960003732 tyramine Drugs 0.000 claims description 5
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 4
- 229940127228 tetracyclic antidepressant Drugs 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract description 31
- 229960005190 phenylalanine Drugs 0.000 abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 206010012643 Diabetic amyotrophy Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940104742 lofepramine 70 mg Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000005518 mononeuropathy Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- 208000019736 Cranial nerve disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010027910 Mononeuritis Diseases 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical class OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001393 dosulepin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- -1 moclopemide Chemical compound 0.000 description 2
- 208000013734 mononeuritis simplex Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000002856 peripheral neuron Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010012645 Diabetic autonomic neuropathy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 206010058530 Peripheral nerve palsy Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000011185 Polyneuropathy in malignant disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710171573 Primary amine oxidase Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000025154 acute pandysautonomia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Definitions
- the present invention relates to the use of a combined medicament in the treatment of various forms of peripheral neuropathy, especially painful neuropathies and diabetic neuropathy, including diabetic amyotrophy, mononeuritis, mononeuritis multiplex, cranial nerve palsies and autonomic neuropathy.
- the invention also relates to the preparation of medicaments for such treatments.
- Diabetes mellitus is a metabolic disorder resulting in hyperglycaemia (raised blood sugar), polyuria (increased output of urine) and glycosuria (appearance of sugars (e.g. glucose) in the urine). Diabetes has been recognised as a major disease for centuries. In addition to defective carbohydrate metabolism, it can also lead to altered metabolism of lipids and proteins and patients are at risk of complications from microvascular and macrovascular diseases which are serious and may be fatal.
- Insulin dependent diabetes results from failure of the islets of Langerhans ( ⁇ ) cells of the pancreas to produce sufficient insulin. This often arises as a result of auto-immunity directed against islet tissue.
- Non-insulin-dependent diabetes may in part arise from altered efficiency of insulin receptor signalling (insulin resistance) or from a relative deficiency of insulin.
- Detectable diabetic neuropathy occurs in approximately 60% of diabetic patients. Some 20% of diabetic patients show moderate to severe symptoms, the severity is generally thought to be linked to the duration of diabetic symptoms and the level of control using e.g. insulin, or oral hypoglycaemic agents such as the sulphonylureas.
- Diabetic neuropathy may be mild, for example taking the form of “burning” or tingling in the feet or numbness and/or loss of vibration sense in the extremities, especially the feet. Moderate to severe symptoms of neuropathy include pain and spasm in the extremities (painful neuropathy with spasm). Diabetic amyotrophy is indicated by pain over the thigh and loss of quadriceps power, sometimes also loss of power in the lower leg resulting in foot drop. Autonomic neuropathy principally affects the nerves supplying the heart and viscera. Mononeuritis is usually caused by a single peripheral nerve palsy.
- peripheral neuropathies include the following:
- lymphomatous neuropathy [0012] lymphomatous neuropathy
- Type I diabetes insulin dependent diabetes
- type II diabetes non-insulin dependent diabetes
- neuropathy Both type I (insulin dependent) diabetes and type II (non-insulin dependent) diabetes are associated with neuropathy.
- Type I diabetes commonly presents in relatively young adults, often with diabetic ketoacidosis, type II diabetes (also know as maturity onset diabetes) often occurs in middle age or in elderly patients.
- Type II diabetes is particularly associated with the relatively late and severe onset of neuropathy.
- gamolenic acid may reduce symptoms, and prevent the progression of abnormalities in nerve conduction studies in diabetic neuropathy.
- WO 96/11009 discloses treatment of multiple sclerosis by some of the combinations of components employed in the present invention.
- Vitamin B 12 has been proposed for the treatment of B 12 -deficiency associated neuropathy.
- the present inventor has surprisingly found that a combination of an antidepressant or a monamine oxidase inhibitor (MAOI) with an inducer or a precursor of a neurotransmitter can be effective in the treatment of peripheral neuropathies, and in particular painful neuropathy.
- the components of this medicament may be presented as a combined preparation for simultaneous, separate or sequential use in the treatment of various peripheral neuropathies. It has also been observed that a parallel or simultaneous administration of vitamin B 12 treatment, for example orally or by injection, may enhance the therapeutic effect of this combination.
- the present invention provides the use of any one of the following components or combinations of components:
- A is an antidepressant or a monoamine oxidase inhibiter
- B is vitamin B 12 .
- C is a precursor or inducer of a neurotransmitter, in the manufacture of a medicament for the treatment of at least one form of peripheral neuropathy.
- the invention provides a method of making a medicament for the treatment of a patient suffering from a peripheral neuropathy, comprising admixing any one of the following components:
- A is an antidepressant or a monoamine oxidase inhibiter
- B is vitamin B 12 .
- C is a precursor or inducer of a neurotransmitter, with at least one pharmaceutically acceptable component or vehicle to prepare a medicament suitable for administration to a patient.
- the invention provides a method of treatment of a patient suffering from a form of peripheral neuropathy, comprising administering to the patient any one of the following combinations of components:
- A is an antidepressant or a monoamine oxidase inhibitor
- B is vitamin B 12 .
- C is a precursor or inducer of a neurotransmitter
- the invention provides a pharmaceutical composition containing as the only pharmaceutically active components vitamin B 12 and a precursor or inducer of a neurotransmitter.
- Treatment may be simultaneous or separate including sequential administration of the components.
- the medicaments of the invention there may be included at least one pharmaceutically acceptable component or vehicle such as an incipient, carrier, buffer, stabiliser or other material, as discussed below.
- a pharmaceutically acceptable component or vehicle such as an incipient, carrier, buffer, stabiliser or other material, as discussed below.
- kits or pack containing components A and B, or A and C, or A and B and C, or B and C, wherein component A the components being formulated for simultaneous, separate or sequential delivery in the treatment of peripheral neuropathy.
- Particularly components A and C may be combined, and component B separate.
- the diabetic neuropathy with which the present invention is concerned may be characterised by degeneration of the long nerves (the nerves of the peripheral nervous system) as a result of the metabolic disturbances of diabetes.
- This can be contrasted with other neurodegenerative disorders such multiple sclerosis, the effects of which are concentrated in the central nervous system.
- multiple sclerosis leads to demyelination of the neurons of the central nervous system (that is, degeneration of the myelin sheath which surrounds the neurons)
- the toxic effects of diabetes occur in the body of the peripheral neuron, possibly due to the toxic effect of metabolites arising through the underlying diabetic disturbance of carbohydrate metabolism, or as a secondary effect of diabetic microvascular degeneration.
- the result of the degenerative changes in the body of the peripheral neuron is reduced signal conductivity along the length of the nerve. It is believed that the initial generation of a signal and the passage of a signal across synapses may not be directly effected by the condition.
- the present invention is applicable to any and all of peripheral neuropathies, particularly painful neuropathies, including those listed above in the introduction.
- Preferred antidepressants for use in the present invention include tricyclic and tetracyclic antidepressants such as lofepramine and selected seritonin re-uptake inhibitors (SSRI). Lofepramine and certain other tricyclic antidepressants also show some monoamine oxidase inhibitor (MAOI) activity.
- SSRI selected seritonin re-uptake inhibitors
- MAOI monoamine oxidase inhibitor
- Suitable antidepressants and MAOIs include mianserin, trimipramine, imipramine, clomipramine, amitriptyline, protriptyline, nortriptyline, fluvoxamine, fluoxetine, maprotiline, sertaline, venlaflaxine, pargyline, triazolopyridine, phenelzine, tranylcypromine, desipramine, moclopemide, dothiepin, doxepin, paroxetine, oxazine or viloxazine, amongst others.
- a neurotransmitter inducer is a component which enhances or triggers production of a neurotransmitter.
- a preferred neurotransmitter precursor for use in the present invention is L-phenylalanine (LPA).
- LPA L-phenylalanine
- L-tryptophan may also find use in the present invention.
- amino acids such as L-tyrosine or other compounds such as tyramine may also find use in the present invention as a neurotransmitter, inducer or precursor.
- Compounds may be provided as a metabolite of a precursor.
- L-phenylalanine may be provided as a metabolite of aspartame.
- the combination for treatment includes vitamin B 12 , this may be in the form of cyanocobalamin or hydroxycobalamin, to be administered orally or intramuscularly.
- compositions provided herein may comprise an antidepressant or a monoamine oxidase inhibitor (MAOI) and a neurotransmitter precursor or inducer, or any other combination of components disclosed herein, as combined (simultaneous or sequential) actives.
- MAOI monoamine oxidase inhibitor
- compounds may be employed which mimic a given active in improving diagnostic status and/or ameliorating one or more symptoms of diabetic neuropathy (mimetics). Such compounds and their use are within the scope of the present invention.
- derivatives or analogues of the antidepressant or MAOI which retain the antidepressant or MAOI activity, respectively.
- compositions provided may be administered to individuals. Administration is preferably in a “therapeutically effective amount”, this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors. Dose regimens for the MAOIs and antidepressants may be within the range used for the treatment of depression (for which the standard starting dose of lofepramine is 140 mg per day).
- a possible range for administration of antidepressants is 10-210 mg per day, although 50-70 mg per day may be suitable.
- a range of 100 mg to 5 g per day, preferably 500-2000 mg/d (mg per day) may be employed, the dose increasing in proportion to the level of antidepressant or MAOI employed.
- a 70 mg dose of lofepramine may be combined with 500 mg of L-phenylalanine given in the morning, this being supplemented with a further 500 mg of L-phenylalanine given in the afternoon.
- vitamin B 12 is co-administered
- the amounts may be those generally recommended for daily intake of the vitamin or may be greater than that recommended as average daily intake.
- the preferred average dosage range for vitamin B 12 in the invention is from 1 mg every 3 months up to 1 mg every 3 days. When symptoms are severe, this may be 1 mg intramuscular hydroxycobalamin per week in an 8-10 week course at the start of treatment, perhaps reduced to 1 mg every 10 days as treatment progresses.
- the desired dosage level of vitamin B 12 may conveniently be given by weekly intramuscular injection, but doses ranging from 5 ⁇ g to 10 mg may be given daily orally.
- compositions according to the present invention may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may comprise a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- L-tryptophan and L-phenylalanine are available in 500 mg tablets.
- a combined oral preparation in single tablet form containing all these components A, B and C, or for example components B and C, is feasible.
- a treatment pack may contain the components separately.
Abstract
Methods and compositions for treatment of a patient suffering from a form of peripheral neuropathy are disclosed. The method comprises administering to the patient any one of the following combinations of components: I. A, B and C; II. A and B; III. B and C; IV. A and C, wherein A is an antidepressant or a monoamine oxidase inhibitor, B is vitamin B12, and C is a precursor or inducer of a neurotransmitter, e.g. L-phenylalanine.
Description
- The present invention relates to the use of a combined medicament in the treatment of various forms of peripheral neuropathy, especially painful neuropathies and diabetic neuropathy, including diabetic amyotrophy, mononeuritis, mononeuritis multiplex, cranial nerve palsies and autonomic neuropathy. The invention also relates to the preparation of medicaments for such treatments.
- Diabetes mellitus is a metabolic disorder resulting in hyperglycaemia (raised blood sugar), polyuria (increased output of urine) and glycosuria (appearance of sugars (e.g. glucose) in the urine). Diabetes has been recognised as a major disease for centuries. In addition to defective carbohydrate metabolism, it can also lead to altered metabolism of lipids and proteins and patients are at risk of complications from microvascular and macrovascular diseases which are serious and may be fatal.
- Insulin dependent diabetes results from failure of the islets of Langerhans (β) cells of the pancreas to produce sufficient insulin. This often arises as a result of auto-immunity directed against islet tissue. Non-insulin-dependent diabetes may in part arise from altered efficiency of insulin receptor signalling (insulin resistance) or from a relative deficiency of insulin.
- Detectable diabetic neuropathy occurs in approximately 60% of diabetic patients. Some 20% of diabetic patients show moderate to severe symptoms, the severity is generally thought to be linked to the duration of diabetic symptoms and the level of control using e.g. insulin, or oral hypoglycaemic agents such as the sulphonylureas.
- Diabetic neuropathy may be mild, for example taking the form of “burning” or tingling in the feet or numbness and/or loss of vibration sense in the extremities, especially the feet. Moderate to severe symptoms of neuropathy include pain and spasm in the extremities (painful neuropathy with spasm). Diabetic amyotrophy is indicated by pain over the thigh and loss of quadriceps power, sometimes also loss of power in the lower leg resulting in foot drop. Autonomic neuropathy principally affects the nerves supplying the heart and viscera. Mononeuritis is usually caused by a single peripheral nerve palsy.
- Other peripheral neuropathies include the following:
- HIV associated neuropathy;
- B12-deficiency associated neuropathy;
- cranial nerve palsies;
- drug-induced neuropathy;
- industrial neuropathy;
- lymphomatous neuropathy;
- myelomatous neuropathy;
- multi-focal motor neuropathy;
- chronic idiopathic sensory neuropathy;
- carcinomatous neuropathy;
- acute pan autonomic neuropathy;
- alcoholic neuropathy;
- compressive neuropathy;
- vasculitic/ischaemic neuropathy;
- mono- and poly- neuropathies.
- Both type I (insulin dependent) diabetes and type II (non-insulin dependent) diabetes are associated with neuropathy. Type I diabetes commonly presents in relatively young adults, often with diabetic ketoacidosis, type II diabetes (also know as maturity onset diabetes) often occurs in middle age or in elderly patients. Type II diabetes is particularly associated with the relatively late and severe onset of neuropathy.
- Previous treatments for diabetic neuropathy have included tricyclic antidepressants on their own, the antiepileptic drug carbemazepine, and the antiarrythmic drug mexilitene. However these seem only to be mildly effective, and not in all cases. Long term good diabetic control has also shown to be a benefit in the prevention of diabetic neuropathy and in control of the symptoms, presumably controlling the agents which cause the damage to the nerves. There is little indication that long term control of diabetes can reverse symptoms i.e. the damage, once done, appears not to be reversible by treatment of the underlying diabetes.
- Recent clinical trials have shown that gamolenic acid may reduce symptoms, and prevent the progression of abnormalities in nerve conduction studies in diabetic neuropathy.
- WO 96/11009 discloses treatment of multiple sclerosis by some of the combinations of components employed in the present invention.
- Vitamin B12 has been proposed for the treatment of B12-deficiency associated neuropathy.
- The present inventor has surprisingly found that a combination of an antidepressant or a monamine oxidase inhibitor (MAOI) with an inducer or a precursor of a neurotransmitter can be effective in the treatment of peripheral neuropathies, and in particular painful neuropathy. The components of this medicament may be presented as a combined preparation for simultaneous, separate or sequential use in the treatment of various peripheral neuropathies. It has also been observed that a parallel or simultaneous administration of vitamin B12 treatment, for example orally or by injection, may enhance the therapeutic effect of this combination.
- It has also been found that combinations (i) vitamin B12 with an inducer or a precursor of a neurotransmitter and (ii) vitamin B12 with an antidepressant, are effective in treatment of peripheral neuropathies.
- Accordingly, in a first aspect the present invention provides the use of any one of the following components or combinations of components:
- C,
- A and B,
- A and C,
- B and C,
- A, B and C,
- wherein
- A is an antidepressant or a monoamine oxidase inhibiter,
- B is vitamin B12, and
- C is a precursor or inducer of a neurotransmitter, in the manufacture of a medicament for the treatment of at least one form of peripheral neuropathy.
- In another aspect the invention provides a method of making a medicament for the treatment of a patient suffering from a peripheral neuropathy, comprising admixing any one of the following components:
- C,
- A and B,
- A and C,
- B and C,
- A, B and C,
- wherein
- A is an antidepressant or a monoamine oxidase inhibiter,
- B is vitamin B12, and
- C is a precursor or inducer of a neurotransmitter, with at least one pharmaceutically acceptable component or vehicle to prepare a medicament suitable for administration to a patient.
- In yet another aspect the invention provides a method of treatment of a patient suffering from a form of peripheral neuropathy, comprising administering to the patient any one of the following combinations of components:
- I. A, B and C
- II. A and B
- III. B and C
- IV. A and C
- wherein
- A is an antidepressant or a monoamine oxidase inhibitor,
- B is vitamin B12, and
- C is a precursor or inducer of a neurotransmitter,
- said components being administered simultaneously or separately, in amounts which in combination have the effect of ameliorating the peripheral neuropathy.
- In a further aspect the invention provides a pharmaceutical composition containing as the only pharmaceutically active components vitamin B12 and a precursor or inducer of a neurotransmitter.
- Treatment may be simultaneous or separate including sequential administration of the components.
- In the medicaments of the invention, there may be included at least one pharmaceutically acceptable component or vehicle such as an incipient, carrier, buffer, stabiliser or other material, as discussed below.
- Also provided is a kit or pack containing components A and B, or A and C, or A and B and C, or B and C, wherein component A the components being formulated for simultaneous, separate or sequential delivery in the treatment of peripheral neuropathy. Particularly components A and C may be combined, and component B separate.
- The diabetic neuropathy with which the present invention is concerned may be characterised by degeneration of the long nerves (the nerves of the peripheral nervous system) as a result of the metabolic disturbances of diabetes. This can be contrasted with other neurodegenerative disorders such multiple sclerosis, the effects of which are concentrated in the central nervous system. Whilst multiple sclerosis leads to demyelination of the neurons of the central nervous system (that is, degeneration of the myelin sheath which surrounds the neurons), the toxic effects of diabetes occur in the body of the peripheral neuron, possibly due to the toxic effect of metabolites arising through the underlying diabetic disturbance of carbohydrate metabolism, or as a secondary effect of diabetic microvascular degeneration. Whatever the mechanism, the result of the degenerative changes in the body of the peripheral neuron is reduced signal conductivity along the length of the nerve. It is believed that the initial generation of a signal and the passage of a signal across synapses may not be directly effected by the condition.
- In addition to diabetic neuropathies, the present invention is applicable to any and all of peripheral neuropathies, particularly painful neuropathies, including those listed above in the introduction.
- Preferred antidepressants for use in the present invention include tricyclic and tetracyclic antidepressants such as lofepramine and selected seritonin re-uptake inhibitors (SSRI). Lofepramine and certain other tricyclic antidepressants also show some monoamine oxidase inhibitor (MAOI) activity. Other suitable antidepressants and MAOIs include mianserin, trimipramine, imipramine, clomipramine, amitriptyline, protriptyline, nortriptyline, fluvoxamine, fluoxetine, maprotiline, sertaline, venlaflaxine, pargyline, triazolopyridine, phenelzine, tranylcypromine, desipramine, moclopemide, dothiepin, doxepin, paroxetine, oxazine or viloxazine, amongst others.
- A neurotransmitter inducer is a component which enhances or triggers production of a neurotransmitter.
- A preferred neurotransmitter precursor for use in the present invention is L-phenylalanine (LPA). However L-tryptophan may also find use in the present invention.
- Other amino acids such as L-tyrosine or other compounds such as tyramine may also find use in the present invention as a neurotransmitter, inducer or precursor.
- Compounds may be provided as a metabolite of a precursor. For example, L-phenylalanine may be provided as a metabolite of aspartame.
- If the combination for treatment includes vitamin B12, this may be in the form of cyanocobalamin or hydroxycobalamin, to be administered orally or intramuscularly.
- The compositions provided herein may comprise an antidepressant or a monoamine oxidase inhibitor (MAOI) and a neurotransmitter precursor or inducer, or any other combination of components disclosed herein, as combined (simultaneous or sequential) actives. However, compounds may be employed which mimic a given active in improving diagnostic status and/or ameliorating one or more symptoms of diabetic neuropathy (mimetics). Such compounds and their use are within the scope of the present invention. Also within the scope of the present invention are derivatives or analogues of the antidepressant or MAOI which retain the antidepressant or MAOI activity, respectively.
- In accordance with the present invention, compositions provided may be administered to individuals. Administration is preferably in a “therapeutically effective amount”, this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors. Dose regimens for the MAOIs and antidepressants may be within the range used for the treatment of depression (for which the standard starting dose of lofepramine is 140 mg per day). With the proviso that the prescribing physician will be able to decide suitable and safe dosage levels, a possible range for administration of antidepressants is 10-210 mg per day, although 50-70 mg per day may be suitable. For the neurotransmitter precursors or inducers, a range of 100 mg to 5 g per day, preferably 500-2000 mg/d (mg per day) may be employed, the dose increasing in proportion to the level of antidepressant or MAOI employed.
- As an example, a 70 mg dose of lofepramine may be combined with 500 mg of L-phenylalanine given in the morning, this being supplemented with a further 500 mg of L-phenylalanine given in the afternoon.
- Where vitamin B12 is co-administered, the amounts may be those generally recommended for daily intake of the vitamin or may be greater than that recommended as average daily intake. The preferred average dosage range for vitamin B12 in the invention is from 1 mg every 3 months up to 1 mg every 3 days. When symptoms are severe, this may be 1 mg intramuscular hydroxycobalamin per week in an 8-10 week course at the start of treatment, perhaps reduced to 1 mg every 10 days as treatment progresses. The desired dosage level of vitamin B12 may conveniently be given by weekly intramuscular injection, but doses ranging from 5 μg to 10 mg may be given daily orally.
- Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.
- Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. L-tryptophan and L-phenylalanine are available in 500 mg tablets.
- A combined oral preparation in single tablet form, containing all these components A, B and C, or for example components B and C, is feasible. Alternatively, a treatment pack may contain the components separately.
- A 48 year old male, diagnosed non-insulin dependent diabetic when aged 28, showed symptoms of diabetic neuropathy which commenced approximately 8 years ago. The onset of neuropathy was thought to be due to poor control of diabetes. Neuropathic symptoms increased in severity over several years with development of severe diabetic neuropathy including diabetic amyotrophy, painful neuropathy with spasm, diabetic autonomic neuropathy and decreased sensation in the extremities, with numbing and loss of vibration sense. Electromyography confirmed the diagnosis of diabetic neuropathy.
- Treatment with tricyclic antidepressants and carbemazepine was ineffective. An improvement in control of the patient's diabetes also did not significantly affect his severe symptoms.
- A regime of 70 mg lofepramine and 500 mg LPA, each administered with informed consent twice daily, with weekly 1 mg vitamin B12 injections, significantly improved reported symptoms within 12 hours. Almost complete clinical resolution of clinical signs and symptoms had occurred after one week of combined therapy.
- Long term maintenance of diabetic neuropathic remission has required continued treatment, for this patient.
- A 55 year old male with non-insulin dependent diabetes with very severe diabetic neuropathy, including diabetic amyotrophy and bedbound, resistant to current therapies, was commenced on vitamin B12 injections (1 mg at two-week intervals) and L-phenylalanine (as a metabolite of aspartame) 500 mg twice a day.
- Benefit in amyotrophy was noted within 3 hours of commencement of treatment. The subsequent addition of lofepramine 70 mg twice daily produced a further improvement. Within 3 weeks his diabetic amyotrophy was considerably improved.
- This case studied here is of the same 48 year old male with diabetic neuropathy as in case #1, but after the original observation in case #1. The patient was subsequently continued on the same vitamin B12 injections and phenylalanine (500 mg twice daily) only. He continued to benefit from his therapy whilst on these two drugs only, for approximately two months, and then required the recommencement of lofepramine to maintain good effect clinically.
- A 72 year old male with vitamin B12 neuropathy and mild alcoholic neuropathy was studied.
- Clinical progress with vitamin B12 injections alone was insignificant. The addition of lofepramine to the medication enabled the patient to retain his balance, lose his painful neuropathy, and within 3 days ambulate almost normally. Previously he required the assistance of another person to walk.
- A 76 year old female with non-insulin dependent diabetes for 15 years with reasonable control, developed peripheral painful diabetic neuropathy of two months duration. She was commenced with vitamin B12 1 mg weekly, L-phenylalanine 500 mg twice daily and lofepramine 35 mg twice daily (reduced dosage because of age) with a very good response within 48-72 hours. All symptoms had disappeared. The treatment was stopped six weeks after the commencement of the therapy and there has been no recurrence in the two months to the time of report of this case.
- A 50 year old male who had diabetes for 15 years more recently requiring insulin therapy, developed peripheral painful diabetic neuropathy which had become severe, he was commenced on vitamin B12 1 mg intramuscular weekly, lofepramine 70 mg twice daily and L-phenylalanine 500 mg twice daily. He had a good response within the first two weeks. After that period treatment was stopped and he had no recurrence of symptoms and there were no side effects detected.
- A 59 year old male with peripheral diabetic neuropathy and impotence of 3 years duration becoming increasingly severe over three months period prior to therapy. He was commenced on weekly vitamin B12 1 mg intramuscular, lofepramine 70 mg twice daily and L-phenylalanine 500 mg twice daily. He had a good immediate response within the first two weeks with no side effects. He continues with his treatment at the time of report of this case.
- A male in his fourth decade had mild painful peripheral alcoholic neuropathy of six months duration with increasing severity over the past two months. In addition he complained of a compressive neuropathy involving the C6 nerve root. He was commenced on vitamin B12 orally 200 μg daily and L-phenylalanine 500 mg twice daily with a considerable reduction in symptomatology whilst on therapy.
- A male in his fifth decade was HIV positive and complained of moderate peripheral neuropathy including painful neuropathy. He also had mild diabetes of short duration but clinically his neuropathy was diagnosed as that related to HIV. He had been previously commenced on amitriptyline 75 mg daily with some mild beneficial effects. He was additionally commenced on L-phenylalanine 500 mg twice daily, whereafter he reported an approximate further 50% improvement in the symptoms of his painful neuropathy.
- A female in her sixth decade had severe diabetic peripheral neuropathy and resultant Charcot foot joints. She was initially placed on tricyclic anti-depressants in the form of dothiepin 150 mg once daily with a mild beneficial effect. The subsequent addition of vitamin B12 injections 1 mg weekly, resulted in improvement in painful symptomatology. Vibration sense was also improved. Further clinical benefit was gained by the addition of L-phenylalanine 500 mg twice daily. Vibration sense initially could not be detected at a level below the knee. During therapy the level at which vibration sense which could be detected was at the level of the medial malleolus. Her pain has subsided and she has noted no further progression in the damage to her joints to date of reporting of this case.
- It will be apparent to those skilled in the art that variations and modifications to the specific embodiments disclosed herein may be made without departing from the scope of the invention.
Claims (25)
1. Use of any one of the following components or combinations of components:
C,
A and B,
A and C,
B and C,
A, B and C,
wherein
A is an antidepressant or a monoamine oxidase inhibiter,
B is vitamin B12, and
C is a precursor or inducer of a neurotransmitter,
in the manufacture of a medicament for the treatment of at least one form of peripheral neuropathy.
2. Use according to , wherein the peripheral neuropathy is a diabetic neuropathy.
claim 1
3. Use according to or , wherein the peripheral neuropathy is a painful neuropathy.
claim 1
2
4. Use according to , or 3, wherein A is a tricyclic or tetracyclic antidepressant or a selected seritonin re-uptake inhibitor.
claim 1
2
5. Use according to , wherein A is lofepramine.
claim 4
6. Use according to any one of to , wherein B is in the form of cyanocobalamin or hydroxycobalamin.
claims 1
5
7. Use according to any one of to , wherein C is L-phenylalanine, L-tyrosine, L-tryptophan or tyramine.
claims 1
6
8. Method of making a medicament for the treatment of a patient suffering from a peripheral neuropathy, comprising admixing any one of the following components or combinations of components:
C,
A and B,
A and C,
B and C,
A, B and C,
wherein
A is an antidepressant or a monoamine oxidase inhibiter,
B is vitamin B12, and
C is a precursor or inducer of a neurotransmitter,
with at least one pharmaceutically acceptable component or vehicle to prepare a medicament suitable for administration to a patient.
9. Method according to , wherein said medicament contains one of the following combinations of components:
claim 8
A, B and C,
A and B,
B and C,
A and C,
in a form or forms suitable for simultaneous or separate administration.
10. Method according to or , wherein the neuropathy is a painful neuropathy.
claim 8
9
11. Method according to , or 10, wherein the neuropathy is diabetic neuropathy.
claim 8
9
12. Method according to any one of to , wherein A is a tricyclic or tetracyclic antidepressant or a selected seritonin re-uptake inhibitor.
claims 8
11
13. Method according to , wherein A is lofepramine.
claim 12
14. Method according to any one of to , wherein B is in the form of cyanocobalamin or hydroxycobalamin.
claims 8
13
15. Method according to any one of to , wherein C is L-phenylalanine, L-tyrosine, L-tryptophan or tyramine.
claims 8
14
16. Method of treatment of a patient suffering from a form of peripheral neuropathy, comprising administering to the patient any one of the following combinations of components:
I. A, B and C
II. A and B
III. B and C
IV. A and C
wherein
A is an antidepressant or a monoamine oxidase inhibitor,
B is vitamin B12, and
C is a precursor or inducer of a neurotransmitter,
said components being administered simultaneously or separately, in amounts which in combination have the effect of ameliorating the peripheral neuropathy.
17. Method according to wherein the neuropathy is a painful neuropathy.
claim 16
18. Method according to and wherein the neuropathy is diabetic neuropathy.
claim 16
17
19. Method according to any one of to , wherein A is a tricyclic or tetracyclic antidepressant or a selected seritonin re-uptake inhibitor.
claims 16
18
20. Method according to , wherein A is lofepramine.
claim 19
21. Method according to any one of to , wherein B is in the form of cyanocobalamin or hydroxycobalamin.
claims 16
20
22. Method according to any one of to , wherein C is L-phenylalanine, L-tyrosine, L-tryptophan or tyramine.
claims 16
21
23. A pharmaceutical composition containing as the only pharmaceutically active components vitamin B12 and a precursor or inducer of a neurotransmitter.
24. A pharmaceutical composition according to wherein vitamin B12 is in the form of cyanocobalamin or hydroxycobalamin.
claim 23
25. A pharmaceutical composition according to or , wherein the precursor or inducer of a neurotransmitter is L-phenylalanine, L-tyrosine, L-tryptophan or tyramine.
claim 23
24
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9614121 | 1996-07-05 | ||
GBGB9614121.3A GB9614121D0 (en) | 1996-07-05 | 1996-07-05 | Combined medicament |
GB9614121.3 | 1996-07-05 | ||
GB9616019 | 1996-07-31 | ||
GBGB9616019.7A GB9616019D0 (en) | 1996-07-05 | 1996-07-31 | Combined medicaments |
PCT/GB1997/001822 WO1998001157A1 (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010008884A1 true US20010008884A1 (en) | 2001-07-19 |
US6335323B2 US6335323B2 (en) | 2002-01-01 |
Family
ID=26309637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/214,314 Expired - Fee Related US6335323B2 (en) | 1996-07-05 | 1997-07-04 | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter |
Country Status (10)
Country | Link |
---|---|
US (1) | US6335323B2 (en) |
EP (1) | EP0942751B1 (en) |
AT (1) | ATE224733T1 (en) |
AU (1) | AU3451797A (en) |
CA (1) | CA2259010A1 (en) |
DE (1) | DE69715899T2 (en) |
DK (1) | DK0942751T3 (en) |
ES (1) | ES2184111T3 (en) |
PT (1) | PT942751E (en) |
WO (1) | WO1998001157A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020014226A1 (en) * | 1999-02-25 | 2002-02-07 | Lathrop & Gage, L.C. | Internal combustion system adapted for use of a dual fuel composition including acetylene |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20040101575A1 (en) * | 1999-10-04 | 2004-05-27 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20040250723A1 (en) * | 2003-06-10 | 2004-12-16 | Heidelberger Druckmaschinen Ag | Method for metering dampening solution when printing with an offset press |
US20050065190A1 (en) * | 1999-10-04 | 2005-03-24 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
GB9904252D0 (en) * | 1999-02-24 | 1999-04-21 | Worsley Andrew P | Composition for the treatment of pain |
GB9906808D0 (en) * | 1999-03-24 | 1999-05-19 | Kilgowan Limited | Formulation for treatment of pain |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
US20090306050A1 (en) * | 2006-02-03 | 2009-12-10 | Timothy Dinan | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
SI2091948T1 (en) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
PL2475428T3 (en) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
GB2544630A (en) * | 2015-11-19 | 2017-05-24 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
PL3461819T3 (en) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3981863A (en) * | 1975-02-25 | 1976-09-21 | Micromedic Diagonistics, Inc. | Cyanocobalamin derivatives |
US4431670A (en) | 1980-12-19 | 1984-02-14 | Bernardo Heller | D-Phenylalanine treatment |
US4652559A (en) | 1982-08-16 | 1987-03-24 | The Upjohn Company | 2-(Phenylmethylene)cycloalkyl-azetidines |
EP0784476B1 (en) * | 1994-10-05 | 2002-11-06 | Cari Loder | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound |
-
1997
- 1997-07-04 DK DK97930634T patent/DK0942751T3/en active
- 1997-07-04 CA CA002259010A patent/CA2259010A1/en not_active Abandoned
- 1997-07-04 AT AT97930634T patent/ATE224733T1/en not_active IP Right Cessation
- 1997-07-04 US US09/214,314 patent/US6335323B2/en not_active Expired - Fee Related
- 1997-07-04 WO PCT/GB1997/001822 patent/WO1998001157A1/en active IP Right Grant
- 1997-07-04 EP EP97930634A patent/EP0942751B1/en not_active Expired - Lifetime
- 1997-07-04 DE DE69715899T patent/DE69715899T2/en not_active Expired - Fee Related
- 1997-07-04 AU AU34517/97A patent/AU3451797A/en not_active Abandoned
- 1997-07-04 ES ES97930634T patent/ES2184111T3/en not_active Expired - Lifetime
- 1997-07-04 PT PT97930634T patent/PT942751E/en unknown
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020014226A1 (en) * | 1999-02-25 | 2002-02-07 | Lathrop & Gage, L.C. | Internal combustion system adapted for use of a dual fuel composition including acetylene |
US20040101575A1 (en) * | 1999-10-04 | 2004-05-27 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity |
US20050065190A1 (en) * | 1999-10-04 | 2005-03-24 | Hinz Martin C. | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US20050233008A1 (en) * | 1999-10-04 | 2005-10-20 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
US20060135567A1 (en) * | 1999-10-04 | 2006-06-22 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity |
US7268161B2 (en) | 1999-10-04 | 2007-09-11 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
US7547723B2 (en) | 1999-10-04 | 2009-06-16 | Hinz Martin C | Comprehensive pharmacologic therapy for treatment of a dysfunction |
US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20060178423A1 (en) * | 2002-03-21 | 2006-08-10 | Hinz Martin C | Serotonin and catecholamine system segment optimization technology |
US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
US20040250723A1 (en) * | 2003-06-10 | 2004-12-16 | Heidelberger Druckmaschinen Ag | Method for metering dampening solution when printing with an offset press |
Also Published As
Publication number | Publication date |
---|---|
PT942751E (en) | 2003-02-28 |
ATE224733T1 (en) | 2002-10-15 |
US6335323B2 (en) | 2002-01-01 |
DE69715899T2 (en) | 2003-05-28 |
CA2259010A1 (en) | 1998-01-15 |
DK0942751T3 (en) | 2002-12-02 |
ES2184111T3 (en) | 2003-04-01 |
EP0942751A1 (en) | 1999-09-22 |
AU3451797A (en) | 1998-02-02 |
EP0942751B1 (en) | 2002-09-25 |
DE69715899D1 (en) | 2002-10-31 |
WO1998001157A1 (en) | 1998-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6335323B2 (en) | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter | |
ES2309351T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE DEXTROMETORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS. | |
US6294583B1 (en) | Methods of treating tardive dyskinesia and other movement disorders | |
EP0784476B1 (en) | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and optionally a vitamin b 12 compound | |
US20140093592A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
JP4562911B2 (en) | Method for treating tardive dyskinesia and other movement disorders | |
JPH10505864A (en) | Compositions useful in the manufacture of a medicament for the treatment of various persistent diseases | |
Callahan et al. | Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics | |
AU2009304002B9 (en) | A medicinal product and treatment | |
US20150250761A1 (en) | Compositions and methods for treatment of chronic fatigue | |
EP1742639B1 (en) | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse | |
EP2723448A1 (en) | Compositions and methods for treatment of chronic fatigue | |
US20070173478A1 (en) | Compositions for the enhanced treatment of depression | |
ES2917618T3 (en) | Treatment of alcoholism and depression through the use of ibudilast | |
JP2005306882A (en) | Composition useful for preparation of medicine for treating emotional instability | |
WO2008010768A1 (en) | Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method | |
US20050196433A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
WO2000050028A1 (en) | Compositions for the treatment of pain | |
Chunder | Pregabalin | |
EP2285386B1 (en) | Use of ribose in the treatment of restless legs syndrome | |
WO2023215277A1 (en) | Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto | |
WO2017085437A1 (en) | Combinations for the treatment of dementia, and the enhancement of cognitive function | |
JP2005255695A (en) | Composition useful for production of medicine for treating chronic pain | |
MXPA00006716A (en) | Methods of treating tardive dyskinesia and other movement disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WWK TRUST, THE, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WORSLEY, ANDREW PETER;REEL/FRAME:010184/0724 Effective date: 19981220 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100101 |